Neulasta

Latest stories

13d
Business Wire
Bellicum Appoints Jim Daly to its Board of DirectorsManager of the Oncology Business Unit, and led his team to the successful launc
Bellicum Appoints Jim Daly to its Board of Directors
Business Wire / Posted 13 days ago
Manager of the Oncology Business Unit, and led his team to the successful launch of many products, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®. Earlier in his career, Mr. Daly spent over 16 years with Glaxo... Read more
17d
FOX Business
5 Dividend Stocks to Buy in Mayboosting drug Neupogen due to the arrival of biosimilars on the market, sales o
5 Dividend Stocks to Buy in May
FOX Business / Posted 17 days ago
boosting drug Neupogen due to the arrival of biosimilars on the market, sales of Amgen's other top drugs like Enbrel,Neulasta, andAranesp have all been exceeding expectations, helping to offset that. Now, the Street isn't expecting this trend... Read more
17d
FOX Business
5 Dividend Stocks to Buy in Mayboosting drug Neupogen due to the arrival of biosimilars on the market, sales o
5 Dividend Stocks to Buy in May
FOX Business / Posted 17 days ago
boosting drug Neupogen due to the arrival of biosimilars on the market, sales of Amgen's other top drugs like Enbrel,Neulasta, andAranesp have all been exceeding expectations, helping to offset that. Now, the Street isn't expecting this trend... Read more
17d
Morningstar
Insulet Shares Swoon on Insurer Decision, but Fair Value Is Unchangedalso been pursuing other applications of its OmniPod technology as a drug deliv
Insulet Shares Swoon on Insurer Decision, but Fair Value Is Unchanged
Morningstar / Posted 17 days ago
also been pursuing other applications of its OmniPod technology as a drug delivery device. Its collaboration with Amgen on Neulasta is the first opportunity to establish a footprint in that market. Deep-Pocketed Rivals Are Main Risk Insulet's main... Read more
28d
FOX Business
Insulet Pumps Out 69% Revenue Growth in Q1, Reaffirms 2016 Guidancemanagement had to sayInsulet CEO Patrick Sullivan shared on the conference call
Insulet Pumps Out 69% Revenue Growth in Q1, Reaffirms 2016 Guidance
FOX Business / Posted 28 days ago
management had to sayInsulet CEO Patrick Sullivan shared on the conference call some additional good news regarding Amgen'sNeulasta Onpro kit: We just learned from Amgen's online presentation that the Neulasta Onpro kit now represents... Read more
28d
FOX Business
Insulet Pumps Out 69% Revenue Growth in Q1, Reaffirms 2016 Guidancemanagement had to sayInsulet CEO Patrick Sullivan shared on the conference call
Insulet Pumps Out 69% Revenue Growth in Q1, Reaffirms 2016 Guidance
FOX Business / Posted 28 days ago
management had to sayInsulet CEO Patrick Sullivan shared on the conference call some additional good news regarding Amgen'sNeulasta Onpro kit: We just learned from Amgen's online presentation that the Neulasta Onpro kit now represents... Read more
m
The Tampa Tribune
Amgen posts 1Q sales, profit jumps, raises profit forecaststhe first quarter, up 24 percent from last year due to a price hike and wholesa
Amgen posts 1Q sales, profit jumps, raises profit forecasts
The Tampa Tribune / Posted 1 months ago
the first quarter, up 24 percent from last year due to a price hike and wholesalers stocking more inventory. Anemia drugs Neulasta and Aranesp saw sales rise 4 percent to $1.2 billion and 11 percent to $532 million, respectively. Aranesp, a newer,... Read more
6 related stories
m
Connecticut Post
Amgen posts 1Q sales, profit jumps, raises profit forecaststhe first quarter, up 24 percent from last year due to a price hike and wholesa
Amgen posts 1Q sales, profit jumps, raises profit forecasts
Connecticut Post / Posted 1 months ago
the first quarter, up 24 percent from last year due to a price hike and wholesalers stocking more inventory. Anemia drugs Neulasta and Aranesp saw sales rise 4 percent to $1.2 billion and 11 percent to $532 million, respectively. Aranesp, a newer,... Read more
6 related stories

People in this news